Health Care Knowledge

  The oral semaglutide is approved by the US FDA and other medical authorities around the world along with diet and exercise for controlling body weight and treating Type 2 Diabetes (T2D). The Semaglutide tablets are widely supplied in 3 mg, 7 mg, and 14 mg oral tablet formulas.    Semaglutide tablets are typically less effective than the injectable form, but adding it with basal insulin could boost its effectiveness greater than the injection in terms of treating Type-2 Diabetes (T2D). The combination of semaglutide oral tablets and basal insulin also reveals identical tolerability in users like the injection.   The reason being the oral form of Semaglutide is associated with notable adverse reactions i.e. diarrhea, nausea, and stomach cramps that are specifically digestive tract related. The occurrence of vomiting with an oral semaglutide tablets 14 mg dose is relatively less in comparison with the Dulaglutide 1.5 mg once-weekly dose which is another anti-obesity medicine.   Semagl

  Overview of Oncaspar: Oncaspar is a U.S. Food and Drug Administration (FDA) approved prescription medication to treat acute lymphoblastic leukemia (ALL). The medicine Oncaspar is often used as a part of a chemo regimen. It may also be referred to by its generic name, pegaspargase. Oncaspar injection  is the modified version of an enzyme known as asparaginase. An enzyme basically is a molecule that is designed to accelerate a chemical reaction. Leukemia cells need an amino acid known as asparagine to sustain and replicate. This drug breaks down asparagine into a couple of other substances. Oncaspar is designed to work by scaling down the level of asparagine available to leukemia cells, leading to their destruction. The recommended dosage of  Pegaspargase injection  (Oncaspar) is administered by intravenous (IV) or intramuscular (IM) injection. Oncaspar  (pegaspargase)  in India: If Oncaspar (pegaspargase)- a brand name medication is not approved or not registered in any particular cou